Geneseeq Technology Inc. announced that the U.S. Food and Drug Administration has granted 510(k) clearance for GENESEEQPRIME® NGS Tumor Profiling Assay, marking a significant advancement in comprehensive genomic testing for cancer patients. The in vitro diagnostic test kit uses next-generation sequencing of DNA from FFPE tumor tissue to detect tumor gene alterations across a comprehensive multi-gene panel in patients with solid malignant neoplasms.
Comprehensive Genomic Profiling Capabilities
The GENESEEQPRIME® assay interrogates 425 cancer-related genes, detecting multiple classes of genomic alterations including single nucleotide variants (SNVs), insertions/deletions (indels), and selected gene amplification and translocations. The platform also reports microsatellite instability (MSI) and tumor mutation burden (TMB), providing clinicians with comprehensive molecular insights for treatment decision-making.
Analytical and clinical validation studies conducted across multiple U.S. clinical laboratories demonstrated high sensitivity, specificity, and reproducibility across variant types, supporting the assay's intended use in clinical oncology. The validation studies were performed in CLIA/CAP-accredited laboratories, ensuring rigorous quality standards.
Decentralized Implementation and Global Standardization
Delivered as a ready-to-use IVD kit, GENESEEQPRIME® enables decentralized implementation in oncology laboratories, supporting local adoption while ensuring globally harmonized standards. The assay is paired with GENESIS by GENESEEQ®, the company's proprietary bioinformatics pipeline and reporting system validated across multiple CLIA/CAP-accredited laboratories.
The complete assay solution provides laboratories with a streamlined workflow and a consistent data analysis and reporting framework, facilitating standardized testing protocols across different geographic regions.
Strategic Impact on Drug Development
FDA clearance strengthens Geneseeq's ability to support multi-regional clinical trials, biomarker-driven drug development, and future companion diagnostic (CDx) strategies by offering a standardized, validated platform that promotes data harmonization and operational efficiency across geographies.
"FDA 510(k) clearance of GENESEEQPRIME® marks a major milestone for Geneseeq and for the broader oncology community," said Xue Wu, PhD, CEO of Geneseeq Technology Inc. "By enabling laboratories to deliver high-quality genomic profiling locally on a standardized, regulatory-cleared platform, we are expanding patient access to precision medicine and supporting innovation in cancer care worldwide."
Global Regulatory Achievement
This milestone follows prior regulatory achievements, including CE-IVD marking in Europe and NMPA approval in China, further positioning Geneseeq as a global leader in precision oncology. The company's flagship GeneseeqPrime® tumor profiling assay is now FDA-cleared, CE-IVD marked, and NMPA-approved, ensuring accessibility across major jurisdictions.
Geneseeq's broader portfolio includes four other panels that have received CE-IVD marking, and its multi-cancer early detection (MCED) assay CanScan® has been granted FDA Breakthrough Device Designation. The company operates CAP- and CLIA-certified laboratories and partners with hospitals, academic institutions, and pharmaceutical companies worldwide to advance precision medicine and accelerate biomarker-driven therapeutic development.
